A quick review of the existing literature on Sermorelin acetate suggests that this peptide may exhibit potential to stimulate the production of growth hormones. It is considered to be the shortest analog of growth hormone-releasing hormone (GHRH) which may potentially retain all of the functional features of the original protein, and it is widely employed in research studies for this hypothesis.
Studies suggest an in-depth examination of Sermorelin’s properties uncovers a peptide with potential to mitigate the visual impact of age-related decline, to decrease free radical damage, improve wound healing, and even potentially mitigate cancer cell proliferation. Since it is considerd to be more more than a GHRH agonist, Sermorelin acetate is believed to enhance body composition.
Sermorelin Acetate and Aging
Goldilocks hormone describes growth hormone, which has an optimum amount for generating the greatest results. Both high and low levels of GH are associated with increased mortality and illness. Growth hormone levels fall with age, leaving inadequate amounts of this crucial messenger, which is likely a contributing factor in the aging process. Somatopause, the age-related reduction in GH levels, has emerged as a central research focus within this context.
Symptoms such as decreased muscle mass, increased fat deposition, loss of bone density, decreased energy and states of arousal, elevated cholesterol levels, and changes in skin texture and elasticity are all characteristic of somatopause. Since GH levels naturally fall by around 40% upon maturite, several factors may help counteract some of these negative consequences of aging. Still, increasing data indicates that it can only do so much. Supplementation may be required for appropriate GH levels.
At first, researchers believed that Sermorelin and related peptides slowed the process of physiological decline, but did not appear to increase lifespan through extended organ health and function. Researchers doubted that the peptide Sermorelin, which appeared to increase muscle mass and body composition, might also increase lifespan. However, Sermorelin has been suggested to extend life expectancy in mouse studies. Interesting, however, is that although maximum life expectancy has not changed, average life expectancy has been hypothesized to increase dramatically.
The studies mentioned above also suggest that Sermorelin may aid in keeping the biochemical balance in check, which may increase longevity. Sermorelin’s hypothesized potential in this context may include, but are not limited to, the following:
-
Potentially increased metabolic rate
-
A potentially more advantageous body fat/muscle ratio,
-
Potentially boosted immune system.
-
Potentially faster recovery from injuries
-
Potentially improved heart health
-
Potentially greater length of REM or deep sleep cycles
Sermorelin Acetate and Immunity
Sermorelin’s potentially stimulating impact on the immune system is one mechanism by which it has been hypothesized to extend life and improve health. Animal model studies have suggested an approximately 30% improvement in immunological function after just 4 months of Sermorelin exposure.
There has always been a correlation between advancing age and rising susceptibility to infections. The onset of physiological decline introduces an increased risk of introducing viruses or bacterial infections. Reduced risk of infection, cancer, and maybe even neurological disfunction may result from the capacity to enhance immune function without harmful consequences (a significant discovery in the study).
Sermorelin Acetate and Cancer
Studies suggest that Sermorelin may significantly reduce the number of tumors in mice with increased lifespan. Cancer incidence appeared to have dropped from 10% to 1.7%. Research suggests the potential of Sermorelin in the context of gliomas and other brain malignancies have been supported by additional studies. It has been hypothesized that by controlling immunological checkpoints, Sermorelin may prevent tumor cell proliferation, the first step in tumor development and spread.
Sermorelin Acetate and the Heart
Reduced cardiac scarring and remodeling after a heart attack is one of the purported properties of Sermorelin in the context of heart disease. Findings imply that by potentially decreasing inflammatory signals in the heart and encouraging blood vessel growth, Sermorelin has been suggested to increase cardiomyocyte (heart muscle cell) survival.
It has been a challenge for contemporary science to improve ejection fraction (the blood ejected by the heart with each beat), but recent studies suggest that Sermorelin may help. Ejection fraction must be maintained for the heart’s efficiency, adaptability, and general function to be maintained throughout time. Although the potential impact of Sermorelin supplementation on cardiac health over the long term has not been examined, there is reason to suppose that maintaining healthy GH levels may support healthy cardiac function throughout life. Investigations purport that in addition to improving health generally, this may help maintain activity levels.
Click here to be redirected to Core Peptides’ website for more educational papers on peptides, what they are, how they work, and their properties. The products discussed here are strictly prohibited from human usage, and are available for research and experimental context alone.
References
[i] Banks WA, Morley JE, Farr SA, Price TO, Ercal N, Vidaurre I, Schally AV. Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22272-7. doi: 10.1073/pnas.1016369107. Epub 2010 Dec 6. PMID: 21135231; PMCID: PMC3009756.
[ii] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. doi: 10.2147/ciia.2006.1.4.307. PMID: 18046908; PMCID: PMC2699646.
[iii] Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021 Mar;9(5):406. doi: 10.21037/atm-20-6561. PMID: 33842627; PMCID: PMC8033379.
[iv] Muñoz-Moreno L, Arenas MI, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer. Oncotarget. 2016 Aug 9;7(32):52195-52206. doi: 10.18632/oncotarget.10710. PMID: 27448980; PMCID: PMC5239544.
[v] Rieger AC, Bagno LL, Salerno A, Florea V, Rodriguez J, Rosado M, Turner D, Dulce RA, Takeuchi LM, Kanashiro-Takeuchi RM, Buchwald P, Wanschel ACBA, Balkan W, Schulman IH, Schally AV, Hare JM. Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):e2019835118. doi: 10.1073/pnas.2019835118. PMID: 33468654; PMCID: PMC7848727.
